براءة الاختراع الدوائي و الصحة العامة في إطار اتفاقية تريبس

Abstract EN

The issue of drug patents still raises a lot of controversy in the field of public health, due to the inconsistency between health policies that aim to provide individuals with access to quality and inexpensive medicines; and trade policies that aim to promote economic growth and raise the income of health products manufacturers.

The industrialized countries have succeeded in subjecting the drug to the patent system within the provisions of the TRIPS Agreement, which has had negative effects on the right to health, especially in developing and least developed countries, which were obligated to amend their legislation as approved by the TRIPS Agreement, but this agreement included some provisions that could Reducing the negative effects on public health, especially the provisions of compulsory licenses, as developing countries sought to expand the content of the compulsory licensing system in the field of drugs products through the Doha Ministerial Declaration of 2001.

Enter your abstract here (an abstract is a brief, comprehensive summary of the contents of the article).Enter your abstract here (an abstract is a brief, comprehensive summary of the contents of the article).